<SEC-DOCUMENT>0001654954-19-006820.txt : 20190603
<SEC-HEADER>0001654954-19-006820.hdr.sgml : 20190603
<ACCEPTANCE-DATETIME>20190603065710
ACCESSION NUMBER:		0001654954-19-006820
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190603
FILED AS OF DATE:		20190603
DATE AS OF CHANGE:		20190603

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11960
		FILM NUMBER:		19872104

	BUSINESS ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a8506a.htm
<DESCRIPTION>LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM GERMLINE BRCA-MUTATED METASTATIC PANCREATIC CANCER
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2019 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 6-K</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Report
of Foreign Issuer</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to Rule 13a-16 or 15d-16 of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of <font style="font-weight: bold">June
2019</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number: 001-11960</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">1
Francis Crick Avenue</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
Biomedical Campus</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Cambridge
CB2 0AA</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">United
Kingdom</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F X Form 40-F __</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes __
No X</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If
&#x201C;Yes&#x201D; is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________</font></div>
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
AstraZeneca PLC</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">INDEX
TO EXHIBITS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Lynparza nearly
doubled the time patients lived without disease progression from
germline BRCA-mutated metastatic pancreatic
cancer<br></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="font-style: italic; color: #000000">Lynparza</font><font style="color: #000000">&#xA0;nearly doubled the time patients lived
without&#xA0;disease progression from&#xA0;germline BRCA-mutated
metastatic pancreatic cancer</font></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
22% of patients receiving Lynparza remained free of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; font-style: italic; color: #000000">
disease progression after two</font><font style="color: #000000">&#xA0;</font><font style="font-weight: bold; font-style: italic; color: #000000">years vs.
10% on placebo</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">
Lynparza now the first PARP inhibitor to</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
demonstrate benefit in three different cancer types</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3 June 2019 07:00 BST</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck &amp; Co.,
Inc. inside the US and Canada) today announced detailed results
from the Phase III POLO trial at the 2019 American Society of
Clinical Oncology (ASCO) Annual Meeting in Chicago, US (Abs #LBA4).
Results are today also published in&#xA0;<font style="font-style: italic; text-decoration: underline; color: #0000FF">The
New England Journal of Medicine</font><font style="color: #0000FF">&#xA0;</font>(NEJM).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
POLO trial tested&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;(olaparib) tablets as
1st-line maintenance monotherapy for patients with germline
BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas
(pancreatic cancer) whose disease had not progressed following
standard-of-care platinum-based
1st-line&#xA0;chemotherapy.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Results&#xA0;from
the trial showed a statistically-significant and
clinically-meaningful improvement in progression-free survival
(PFS) for&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;vs. placebo, improving
the time without disease progression by a median of 7.4 months for
patients treated with&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;vs. 3.8 months for those
on placebo (HR 0.53 [95% CI, 0.35-0.82], p=0.004). More than twice
as many patients showed no disease progression both at one year
(34% on&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;vs. 15% on placebo) and
two years (22% vs. 10%, respectively).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Jos&#xE9;&#xA0;Baselga,
Executive Vice President, Oncology R&amp;D, said: "These
unprecedented results raise new hope for patients that
have&#xA0;seen little progress over a long period of time. From as
early as six months after initiation, more than twice as
many&#xA0;patients taking&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;lived without progression
of their disease compared to those on placebo and we are now
working with regulatory authorities to bring&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;to&#xA0;patients as
quickly as possible."</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Roy
Baynes, Senior Vice President and Head of Global Clinical
Development, Chief Medical Officer, MSD Research Laboratories,
said: "We are encouraged by the results of the POLO trial which
showed a considerable reduction in risk of disease progression or
death with&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;for germline
BRCA<font style="font-style: italic">-</font>mutated metastatic
pancreatic cancer patients who did not progress on chemotherapy.
Currently less than 3% of metastatic pancreatic cancer patients
survive more than five years after diagnosis. The results of this
trial reinforce MSD and AstraZeneca's commitment to develop
innovative treatments for cancers with few options."</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Hedy L.
Kindler, MD, co-principal investigator of the POLO trial and
Professor of Medicine, University of Chicago Medicine, said:
"Despite efforts to identify therapies, targeted or combination
treatments to improve patient outcomes, pancreatic cancer remains
an area of high unmet need. The results of the POLO trial may open
the door to a new era of personalised, biomarker-led care in
metastatic pancreatic cancer and reinforces the importance of
knowing BRCA status at diagnosis."</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Click to see Kaplan-Meier estimates of PFS by blinded, independent
central review:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-weight: bold; font-family: Times New Roman; font-size: 13px">
https://www.astrazeneca.com/content/dam/az/Image%20Bank/PrgFree02062019.png/jcr:content/renditions/cq5dam.web.1200.PrgFree02062019.png</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
From&#xA0;</font><font style="font-style: italic; color: #000000">The New England Journal of
Medicine</font><font style="color: #000000">, Golan T, et
al.&#xA0;</font><font style="color: #000000; background-color: #FFFFFF">Maintenance Olaparib
for Germline BRCA-Mutated Metastatic Pancreatic
Cancer</font><font style="color: #000000">, Jun 2 [Epub ahead of
print] Copyright &#xA9; 2019 Massachusetts Medical Society.
Reprinted with permission from the Massachusetts Medical
Society.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
safety and tolerability profile of&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;in the POLO trial was in
line with that observed in prior clinical trials. The most common
adverse events (AEs) &#x2265;20% were fatigue/asthenia (60%), nausea
(45%), abdominal pain (29%), diarrhoea (29%), anaemia (28%),
decreased appetite (25%) and constipation (23%). The most common
&#x2265; grade 3 AEs were anaemia (11%), fatigue/asthenia (5%),
decreased appetite (3%), abdominal pain (2%), vomiting (1%) and
arthralgia (1%). AEs led to dose interruption in 16% of patients
on&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;while
5% of patients discontinued treatment.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">
Lynparza</font>, which is being jointly developed and
commercialised by AstraZeneca and MSD, is approved for multiple
indications in advanced ovarian cancer and metastatic breast cancer
and has been used in over 20,000 patients worldwide.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About POLO</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">POLO is
a Phase III randomised, double-blinded, placebo-controlled,
multicentre trial of&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;tablets (300mg twice
daily) as maintenance monotherapy vs. placebo. The trial randomised
154 patients with gBRCAm metastatic pancreatic cancer whose disease
had not progressed on 1st-line platinum-based chemotherapy.
Patients were randomised (3:2) to receive&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;or placebo until disease
progression. The primary endpoint was PFS and key secondary
endpoints included overall survival, time to second disease
progression, overall response rate, disease control rate and
health-related quality of life.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About pancreatic cancer</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pancreatic
cancer is the 12th most common cancer worldwide,<font style="font-size: 70%; vertical-align: top">1</font>&#xA0;with 458,918
new cases in 2018 alone.<font style="font-size: 70%; vertical-align: top">1</font>With the worst
survival rate of all the most common cancers,<font style="font-size: 70%; vertical-align: top">2</font>&#xA0;it is the 4th
leading cause of cancer death,<font style="font-size: 70%; vertical-align: top">3</font>and less than 3% of
patients with metastatic disease survive more than five years after
diagnosis.<font style="font-size: 70%; vertical-align: top">4</font>&#xA0;Early diagnosis
of pancreatic cancer is difficult, as often there are no symptoms
until it is too late.<font style="font-size: 70%; vertical-align: top">5</font>&#xA0;Around 80% of
patients are diagnosed at the metastatic stage.<font style="font-size: 70%; vertical-align: top">6</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">There
are two types of pancreatic cancer. Exocrine tumours, of which the
most common type is pancreatic ductal adenocarcinoma
(PDAC),<font style="font-size: 70%; vertical-align: top">7</font>&#xA0;start in the
exocrine cells, where enzymes help to digest food. Neuroendocrine
tumours start in neuroendocrine cells, which produce hormones, such
as insulin,<font style="font-size: 70%; vertical-align: top">6</font>&#xA0;that control
different functions of the body.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About BRCA mutations</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Breast
cancer susceptibility genes 1/2 (BRCA1 and&#xA0;BRCA2) are human
genes that produce proteins responsible for repairing damaged DNA
and play an important role maintaining the genetic stability of
cells. When either of these genes is mutated, or altered, such that
its protein product either is not made or does not function
correctly, DNA damage may not be repaired properly, and cells
become unstable. As a result, cells are more likely to develop
additional genetic alterations that can lead to
cancer.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<font style="color: #000000">About&#xA0;</font><font style="font-style: italic; color: #000000">Lynparza</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">
Lynparza</font>&#xA0;(olaparib) is a first-in-class PARP inhibitor
and the first targeted treatment to block DNA damage response (DDR)
in cells/tumours harbouring a deficiency in homologous
recombination repair (HRR), such as mutations in BRCA1 and/or
BRCA2. Inhibition of PARP with&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;leads to the trapping of
PARP bound to DNA single-strand breaks, stalling of replication
forks, their collapse and the generation of DNA double-strand
breaks and cancer cell death.&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;is being tested in a
range of PARP-dependent tumour types with defects and dependencies
in the DDR.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">
Lynparza&#xA0;</font>is currently approved in over 60 countries,
including those in the EU, for the maintenance treatment of
platinum-sensitive relapsed ovarian cancer regardless of BRCA
status. It is approved in the US, Canada and Brazil as 1st-line
maintenance treatment of BRCAm advanced ovarian cancer following
response to platinum-based chemotherapy. It is also approved in
nearly 40 countries, including the US and Japan, for germline BRCAm
HER2-negative metastatic breast cancer previously treated with
chemotherapy; in the EU this includes locally advanced breast
cancer. Regulatory reviews are underway in other jurisdictions for
both ovarian cancer and breast cancer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">
Lynparza</font>&#xA0;has the broadest and most advanced clinical
trial development programme of any PARP inhibitor, and AstraZeneca
and MSD are working together to understand how it may affect
multiple PARP-dependent tumours as a monotherapy and in combination
across multiple cancer types.&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;is the foundation of
AstraZeneca's industry-leading portfolio of potential new medicines
targeting DDR mechanisms in cancer cells.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About the AstraZeneca and MSD strategic oncology
collaboration</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In July
2017, AstraZeneca and Merck &amp; Co., Inc., Kenilworth, NJ, US,
known as MSD outside the United States and Canada, announced a
global strategic oncology collaboration to co-develop and
co-commercialise&#xA0;<font style="font-style: italic">Lynparza</font>, the world's first PARP
inhibitor, and potential new medicine selumetinib, a MEK inhibitor,
for multiple cancer types. Working together, the companies will
develop&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;and selumetinib in
combination with other potential new medicines and as
monotherapies. Independently, the companies will
develop&#xA0;<font style="font-style: italic">Lynparza</font>&#xA0;and selumetinib in
combination with their respective PD-L1 and PD-1
medicines.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About AstraZeneca in Oncology</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
has a deep-rooted heritage in Oncology and offers a quickly-growing
portfolio of new medicines that has the potential to transform
patients' lives and the Company's future. With at least six new
medicines to be launched between 2014 and 2020, and a broad
pipeline of small molecules and biologics in development, we are
committed to advance Oncology as a key growth driver for
AstraZeneca focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative
partnerships and investments that accelerate the delivery of our
strategy, as illustrated by our investment in Acerta Pharma in
haematology.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By
harnessing the power of four scientific platforms -
Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates - and by championing the development
of personalised combinations, AstraZeneca has the vision to
redefine cancer treatment and one day eliminate cancer as a cause
of death.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About AstraZeneca</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &amp;
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions&#xA0;of
patients worldwide.&#xA0;For more information, please
visit</font><font style="text-decoration: underline; color: #0000FF">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">astrazeneca.com</font><font style="color: #0000FF">&#xA0;</font><font style="color: #000000">and
follow us on Twitter</font><font style="color: #0000FF">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">@</font><font style="text-decoration: underline; color: #0000FF">AstraZeneca</font><font style="color: #0000FF">.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #0000FF; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Media Relations</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Gonzalo
Vi&#xF1;a</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5916</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Rob
Skelding</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Oncology</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5821</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Rebecca
Einhorn</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Oncology</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+1 301 518 4122</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Matt
Kent</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
BioPharma</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5906</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jennifer
Hursit</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Other</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203&#xA0;749 5762</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Christina
Malmberg H&#xE4;gerstrand</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Sweden</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+46 8&#xA0;552 53 106</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Michele
Meixell</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
US</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+1 302 885 2677</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Investor Relations</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Thomas
Kudsk Larsen</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5712</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Henry
Wheeler</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Oncology</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5797</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Christer
Gruvris</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
BioPharma (cardiovascular, metabolism)</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5711</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Nick
Stone</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
BioPharma (respiratory, renal)</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5716</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Josie
Afolabi</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Other medicines</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5631</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Craig
Marks</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Finance, fixed income</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 7881 615 764</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Jennifer
Kretzmann</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Corporate access, retail investors</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+44 203 749 5824</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: -12px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">US
toll-free</font></div>
</td>
<td style="vertical-align: middle; width: 45%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 21%">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+1 866 381 72 77</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
References</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
1 World Health Organisation. International Agency for Research on
Cancer. Estimated number of new cases in 2018, worldwide, all
cancers, both sexes, all ages. Accessed May 2019
from&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://gco.iarc.fr/today</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
2 Pancreatic Cancer Action. Facts and statistics. Accessed May 2019
from&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://pancreaticcanceraction.org/about-pancreatic-cancer/healthcare-professionals/stats-facts/facts-and-statistics/</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3 Hidalgo M et al. Addressing the challenges of pancreatic cancer:
future directions for improving outcomes. 2015: Vol 15, Issue 1,
Pg. 8-18.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
4 American Cancer Society. Survival rates for Pancreatic Cancer.
Accessed May 2019 from</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
5 Pancreatic Cancer UK. Signs and symptoms if pancreatic cancer.
Accessed May 2019 from</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.pancreaticcancer.org.uk/information-and-support/facts-about-pancreatic-cancer/signs-and-symptoms-of-pancreatic-cancer/</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
6 Pancreatic Cancer. Some key facts. Accessed May 2019
from</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.pancreaticcancer.org.uk/media/409815/mp-pancreatic-cancer-briefing-notes.pdf</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 13px">
7 Pancreatic Cancer UK. Types of pancreatic cancer. Accessed May
2019 from</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.pancreaticcancer.org.uk/information-and-support/facts-about-pancreatic-cancer/types-of-pancreatic-cancer/</font><font style="color: #000000; font-size: 13px">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<br>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">AstraZeneca
PLC</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
<font style="font-weight: bold; font-size: 13px">03 June
2019</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By: /s/
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Name:
Adrian Kemp</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 71%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 29%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Title:
Company Secretary</font></div>
</td>
</tr></table>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
